XML 36 R18.htm IDEA: XBRL DOCUMENT
v3.22.1

OTHER ASSETS | 12 Months Ended
--- | ---
Dec. 31, 2021
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract] |
OTHER ASSETS | NOTE 12– OTHER ASSETS On April 9, 2020, pursuant to a licensing agreement entered into in March 2020, the Company received 10-year warrants to purchase 127,000 shares of Sanuwave Health, Inc. at a price of $0.19 per share. The fair value for warrants received is estimated at the date of grant using a Black-Scholes-Merton pricing model with the following underlying assumptions: SCHEDULE OF WARRANTS ASSUMPTIONS
Price at valuation |  | $ | 0.19 – 0.26 |
Exercise price |  | $ | 0.19 |
Risk free interest |  |  | 0.66 - 0.73 | %
Expected term (in years) |  |  | 10 |
Volatility |  |  | 140.6 - 143.9 | %
The Company considers this to be level 3 inputs and is valued at each reporting period. The fair value of these warrants for the year ended December 31, 2021 was $18. There was a net $6 change in fair value during the year ended December 31, 2021.

X
- References No definition available. + Details
Name: | us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for other assets. This disclosure includes other current assets and other noncurrent assets. + References No definition available. + Details
Name: | us-gaap_OtherAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration